DESCRIPCIÓN DEL ESTADO DE RECEPTORES DE ESTRÓGENO Y PROGESTERONA Y LA SOBRE-EXPRESIÓN DE ONCOPROTEÍNA C-ERBB-2 EN UNA SERIE DE 29 CASOS DE CARCINOMA DUCTAL INVASOR DE GLÁNDULA MAMARIA.

Rolando Alvarado Anchisi

Submitted October 18, 2024

Published 2026-04-06

Artículos de Investigación

Vol. 23 No. 1 (2010): Revista Médico Científica

DESCRIPTION OF THE ESTROGEN AND PROGESTERONE RECEPTORS, AND THE OVER-EXPRESSION OF ONCOPROTEIN C-ERBB-2 STATUS, IN A SERIES OF 29 CASES OF INVASIVE DUCTAL CARCINOMA OF THE MAMMARY GLAND.

Rolando Alvarado Anchisi⁺⁻

PDF (Español (España))

Citación:

DOI: ND

Published: 2026-04-06

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Abstract

Invasive ductal carcinoma of the breast is a heterogeneous entity with difficult prognosis of global survival and disease-free survival, due to the limited value of histological prognostic factors. For this disease, there are also predictive factors to therapy, such as the hormonal receptor status, of estrogen and progesterone, and the over-expression of the c- erbB-2 oncoprotein, some of which are also prognostic factors.
For this study, monoclonal antibodies were used to determine estrogen receptors, progesterone receptors, and oncoprotein c-erbB-2 in 29 cases referred to the Pathology Laboratory of the Hospital Chiriqui, belonging to resident women of the province of Chiriqui, biopsied from 2007 to 2009. This study found 55,17 % of the cases were luminal- type tumors, 37,93 % were triple negatives, and 6,90 % were Her2-type.
Understimating the importance of these studies by management reduces the possibility of the right therapy according to the real prognosis of patients with breast cancer.

Downloads

Download data is not yet available.

References

Anderson WF, Blair A, Brinton LA et al. Established breast cancer risk factors by clinically important tumour characteristics. British Journal of Cancer 2006; 95(1): 123-129.
Anderon K, Mazouni C, Pusztal L et al. Molecular classification of breast cancer: limitations and potential. The Oncologist 2006; 11: 868-877.
Lonning PE Breast cancer prognostication and prediction: are we making progress? Annals of Oncology 2007; 18(S8): viii3-viii7.
Algrota J, Díaz de Otazu R, Fariña J et al. Immunohistochemical prognostic index for breast cancer in young women. J Clin Pathol: Mol Pathol. 2003; 56: 323-327.
Cianfrocca M, Goldstein LJ Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004; 9: 606-616.
Kroger N, Lonning T, Milde-Langosch K et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006; 12: 159-168.
Coradini D, Daidone MG Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology 2004; 16: 49-55.
Aas T, Botstein D, Borresen-Dale AL et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Procedings of the National Academy of Science USA 2001; 98: 10869-10874.
Ahn SH, Gong G, Kim MJ et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology 2008; 39: 1217-1226.
Bevilacqua JLB, Carvalho FM, Fernandes RCM et al. Coordinate expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009; 55: 346-352.
Botstein D, Brown P, Dieterich H et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002; 161: 1991-1996.
Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopthology 2008; 52: 108-118.
Begin L, Brunet JS, Cheang MCU et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer [Internet] 2007; 7: 134 (Disponible en: http://www.biomedcentral.com)
Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple- negative phenotype. Cancer. 2007; 109: 1721-1728.
Lakhani SR. The morphology of breast tumors in BRCA1/2 carriers. Pathology Case Reviews 2003; 8: 240-244.
Delgado Y, Feiner H, Inghirami G et al. Differential amplification and overexpression of Her-2/neu, p53, MIB1, and Estrogen Receptor/Progesterone Receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med. 2003; 127: 1458-1464.
Bajdik C, Cheang MCU, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative
phenotype. Clin Cancer Res. 2008; 14(5): 1368-1376.
El-Sayed ME, Ellis IO, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.
Dent R, Hanna WM, Kahn HK et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.
Haffty BG, Hait W, Harris L et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.
El-Rehim DMA, Ellis IO, Lee AHS et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology 2005; 18: 26-35.
Khan A, Khawar H, Kiani J et al. Estrogen receptor ?-negative and progesteron receptor-positive breast cancer: Lab error or real entity? Pathology Oncology Research 2006; 12: 223-227.
Scawn R, Shousha S. Morphologic spectrum of Estrogen Receptor-Negative breast carcinoma. Arch Pathol Lab Med. 2002; 126: 325-330.
Crispino S, Rastelli F. Factors predictive of response to hormone therpy in breast cancer. Tumori 2008; 94: 370-383.
Allred DC, Berardo M, Clark GM et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathology 2004; 17: 1545-15554.
Bourne P, Bu H, Hicks D et al. Bone metastasis is strongly associated with estrogen receptor- positive/progesterone receptor negative breast carcinomas. Human Pathology 2008; 39: 1809-1815.
Bohn OL, Brufsky A, Chivukula M et al. Biomarker profile in breast carcinomas presenting with bone metastasis. International Journal of Clinical and Experimental Pathology 2010; 3(2): 139-146.
Carey LA, Collichio F, Dees EC et al. The triple negative paradox: Primary tumor chemosensivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.
Carr JA, Divine G, Havstad S et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000; 135: 1469-1474.

Keywords

PDF (Español (España))

Resumen visto - 3 veces
PDF (Español (España)) descargado - 1

Licencia

Content Top

[1] Anderson WF, Blair A, Brinton LA et al. Established breast cancer risk factors by clinically important tumour characteristics. British Journal of Cancer 2006; 95(1): 123-129.

[2] Anderon K, Mazouni C, Pusztal L et al. Molecular classification of breast cancer: limitations and potential. The Oncologist 2006; 11: 868-877.

[3] Lonning PE Breast cancer prognostication and prediction: are we making progress? Annals of Oncology 2007; 18(S8): viii3-viii7.

[4] Algrota J, Díaz de Otazu R, Fariña J et al. Immunohistochemical prognostic index for breast cancer in young women. J Clin Pathol: Mol Pathol. 2003; 56: 323-327.

[5] Cianfrocca M, Goldstein LJ Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004; 9: 606-616.

[6] Kroger N, Lonning T, Milde-Langosch K et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006; 12: 159-168.

[7] Coradini D, Daidone MG Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology 2004; 16: 49-55.

[8] Aas T, Botstein D, Borresen-Dale AL et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Procedings of the National Academy of Science USA 2001; 98: 10869-10874.

[9] Ahn SH, Gong G, Kim MJ et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology 2008; 39: 1217-1226.

[10] Bevilacqua JLB, Carvalho FM, Fernandes RCM et al. Coordinate expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009; 55: 346-352.

[11] Botstein D, Brown P, Dieterich H et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002; 161: 1991-1996.

[12] Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopthology 2008; 52: 108-118.

[13] Begin L, Brunet JS, Cheang MCU et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer [Internet] 2007; 7: 134 (Disponible en: http://www.biomedcentral.com)

[14] Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple- negative phenotype. Cancer. 2007; 109: 1721-1728.

[15] Lakhani SR. The morphology of breast tumors in BRCA1/2 carriers. Pathology Case Reviews 2003; 8: 240-244.

[16] Delgado Y, Feiner H, Inghirami G et al. Differential amplification and overexpression of Her-2/neu, p53, MIB1, and Estrogen Receptor/Progesterone Receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med. 2003; 127: 1458-1464.

[17] Bajdik C, Cheang MCU, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative

[18] phenotype. Clin Cancer Res. 2008; 14(5): 1368-1376.

[19] El-Sayed ME, Ellis IO, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.

[20] Dent R, Hanna WM, Kahn HK et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.

[21] Haffty BG, Hait W, Harris L et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.

[22] El-Rehim DMA, Ellis IO, Lee AHS et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology 2005; 18: 26-35.

[23] Khan A, Khawar H, Kiani J et al. Estrogen receptor ?-negative and progesteron receptor-positive breast cancer: Lab error or real entity? Pathology Oncology Research 2006; 12: 223-227.

[24] Scawn R, Shousha S. Morphologic spectrum of Estrogen Receptor-Negative breast carcinoma. Arch Pathol Lab Med. 2002; 126: 325-330.

[25] Crispino S, Rastelli F. Factors predictive of response to hormone therpy in breast cancer. Tumori 2008; 94: 370-383.

[26] Allred DC, Berardo M, Clark GM et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathology 2004; 17: 1545-15554.

[27] Bourne P, Bu H, Hicks D et al. Bone metastasis is strongly associated with estrogen receptor- positive/progesterone receptor negative breast carcinomas. Human Pathology 2008; 39: 1809-1815.

[28] Bohn OL, Brufsky A, Chivukula M et al. Biomarker profile in breast carcinomas presenting with bone metastasis. International Journal of Clinical and Experimental Pathology 2010; 3(2): 139-146.

[29] Carey LA, Collichio F, Dees EC et al. The triple negative paradox: Primary tumor chemosensivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.

[30] Carr JA, Divine G, Havstad S et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000; 135: 1469-1474.

Cover image

Abstract

Downloads

References

Keywords

Licencia